GlassScriptPrepare for your visit
Nayyar Syed
Medical Oncology · Pittsburg, TX · NPI 1154411635
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$8,177.52
in general payments reported to CMS, 2019-2025 · $3,544 in 2025
The $3,544 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Who reported paying
General payments only, top 6 by amount.
- Astrazeneca Pharmaceuticals LP $841.10
- E.R. Squibb & Sons, L.L.C. $462.15
- Glaxosmithkline, LLC. $429.31
- Pfizer INC. $423.31
- Incyte Corporation $409.34
- Novartis Pharmaceuticals Corporation $379.24
Drugs and devices associated with these payments
Enhertu Tukysa Jakafi Imbruvica Imfinzi Keytruda Zejula Jemperli Imjudo Ibrance Epkinly Ojjaara
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Nayyar Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/279653/nayyar-syed